Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
16 March 2004Website:
http://www.neogenomics.comNext earnings report:
05 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 1 min agoDividend
Analysts recommendations
Institutional Ownership
NEO Latest News
The consensus price target hints at a 51.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
TORONTO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce that it has closed the non-brokered private placement (the “Offering”) of 2,000,000 units (the “Units”) of the Company at the price of $0.40 CAD per Unit (the “Offering Price”) for gross proceeds of $800,000 CAD.
TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce the signing of a non-binding Letter of Intent (“LOI”) with collaborating partner, Lotus Energy Recycling (“Lotus”) on October 8, 2024. The LOI outlines the intent to form a joint venture (“JV”) focused on recycling end-of-life photovoltaic (PV) cells and solar panels in North America. Recovering valuable silicon materials for the lithium-ion battery supply chain will be a key emphasis of the project. There are no material terms or considerations with respect to the LOI.
TORONTO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce the Joint Development Agreement (“Agreement” or the “JDA”) with a Fortune Global 500, multinational chemical materials company (the “JDA Partner”). The JDA Partner will remain confidential due to competitive strategy and protection of proprietary technologies.
DUBLIN , Oct. 2, 2024 /PRNewswire/ -- AerCap Holdings N.V. ("AerCap" or the "Company") (NYSE: AER) today announced that it has signed lease agreements with Azerbaijan Airlines ("AZAL") for six new Airbus CFM LEAP powered aircraft, including three A320neos and three A321neos which are scheduled to deliver in 2026.
Shares of NeoGenomics Inc (NEO, Financial) surged 3.95% in mid-day trading on Oct 2. The stock reached an intraday high of $14.36, before settling at $14.36, up from its previous close of $13.81.
TORONTO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, has closed the Share Purchase Agreement (the “Transaction”) of NBM Korea Co., Ltd., (“NBM Korea”) with Automobile & PCB Inc. (“A&P”) pursuant to TSX Venture Exchange (the “Exchange”) Policy 5.3 – Acquisitions and Dispositions of Non-Cash Assets (“Policy 5.3”) but is contingent on fulfilling certain conditions required by the Exchange for final acceptance.
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, Sept. 6, 2024 at 10:45 a.m. ET in New York City.
TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- (T S X V : NBM) (OTC: NBMFF)
TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- (T S X V : NBM) (OTC: NBMFF)
- 1(current)
- 2
What type of business is NeoGenomics?
NeoGenomics, Inc. is one of the leading companies in cancer diagnostics and pharmaceutical services, serving oncologists, pathologists, pharmaceutical companies, academic centers, and other specialists with innovative diagnostic and prognostic tests. The company was founded in 2002, with headquarters located in Fort Myers, Florida, USA. The clinical services segment provides cancer testing services for pathologists, oncologists, dermatologists, and other clinicians representing various communities, hospitals, and centers. The company is a leading provider of molecular sequencing and next-generation testing. The pharmaceutical services segment offers comprehensive testing services to support pharmaceutical clients' oncology programs from discovery to commercialization.
What sector is NeoGenomics in?
NeoGenomics is in the Healthcare sector
What industry is NeoGenomics in?
NeoGenomics is in the Diagnostics & Research industry
What country is NeoGenomics from?
NeoGenomics is headquartered in United States
When did NeoGenomics go public?
NeoGenomics initial public offering (IPO) was on 16 March 2004
What is NeoGenomics website?
https://www.neogenomics.com
Is NeoGenomics in the S&P 500?
No, NeoGenomics is not included in the S&P 500 index
Is NeoGenomics in the NASDAQ 100?
No, NeoGenomics is not included in the NASDAQ 100 index
Is NeoGenomics in the Dow Jones?
No, NeoGenomics is not included in the Dow Jones index
When was NeoGenomics the previous earnings report?
No data
When does NeoGenomics earnings report?
The next expected earnings date for NeoGenomics is 05 November 2024